Background
The chikungunya virus is an arbovirus that has spread rapidly in recent years and has infected millions of people in more than 50 countries [
1]. Main form of transmission is through the bite of infected mosquitoes of the genus
Aedes [
2]. However, there are reports of mother-to-child transmission [
3‐
7]. In Brazil, during 2016 and 2017 over 300,000 cases of chikungunya were reported. In the State of Ceará, in the Northeast great region of Brazil, first cases occurred in 2015 culminating with a large outbreak in 2017 where the incidence was 1,520.3 cases/100.000 inhabitants and 157 attributable deaths were confirmed. The vertical transmission occurs mainly during the perinatal period and increases in the intrapartum period, with a transmission rate of approximately 50% [
7], and can be fatal [
7]. The disease is relatively rare in neonates and presents a diagnostic challenge. The clinical manifestations are varied, difficult to manage clinically, and carry a poor prognosis, which may result in death [
6]. We report the occurrence of the first death of a mother and child after probable vertical transmission of chikungunya virus during an epidemic in the city of Fortaleza in northeastern Brazil in 2017.
Discussion and conclusions
This is the first reported death of a mother and child after probable perinatal transmission of chikungunya virus in Brazil. In 2017, a chikungunya epidemic in the city of Fortaleza was recorded, with 71,478 cases and 141 deaths reported through the 48th epidemiological week; the peak of the epidemic coincided with the probable period of infection of the pregnant woman in this case report [
9].
Chikungunya infection is currently a threat to maternal and child health [
10]. However, the effects of maternal viremia in the prenatal period and the transmission mechanism for the newborn are not well-described [
11].
Although confirmatory serological tests were not performed on the pregnant woman, she met the clinical and epidemiological criteria for chikungunya, and her case was confirmed after an investigation conducted by the experts of the arbovirus death investigation commission of the Health Secretariat [
12]. Although for a confirmed case of chikungunya is necessary a PCR positive, a virus isolation positive or a serology test done on two samples showing a IgM/IgG conversion the clinical and laboratorial evidences, relatives with the same symptoms and the ongoing chikungunya epidemic support the confirmation of the case.
Chikungunya infection might possibly have been a contributing factor in her severe disease course, but could also have been coincident. During recent epidemics of chikungunya, the majority of patients hospitalized had preexisting diseases, and most of them experienced decompensation or exacerbation of these diseases, causing hospitalization [
13]. Some studies have suggested that the presence of comorbidities, such as hypertension and diabetes, during chikungunya infection may worsen a patient’s clinical profile and increase the number of deaths [
13‐
16]. While there is biological plausibility, the pathophysiology of this association remains elusive. Its consequences are still not fully clarified. Comprehensive investigations into the interactions between CHKV infection and hypertension are pivotal to elucidate the mechanistic basis of this association.
The neonate had a positive IgM to chikungunya result in cerebrospinal fluid, strongly suggesting of infection by vertical transmission. It should be noted that he remained hospitalized his entire life. Although there may have been mosquito exposure during the hospital stay, the chance of this occurring was very small. There was also the possibility of transmission during transfusions, but again, the chance of this occurring was very small [
4,
5,
17].
In infected neonates, chikungunya symptoms usually develop between days 3 and 7 of life. A study of infected neonates showed that the most frequent laboratory abnormality was thrombocytopenia, which is associated with an elevated prothrombin time and disseminated intravascular coagulation [
5]. Other studies have reported common symptoms such as high fever, irritability, erythematous maculopapular rashes, generalized hyperpigmentation, vesiculobullous lesions, swelling, neurological impairment (such as seizures), cardiac abnormalities, renal, respiratory or hepatic impairment and shock. The most common symptom of case reports of newborn infants with CHIKV by vertical transmission was thrombocytopenia [
4,
5,
7,
18,
19]. In a study of 38 newborn infants with CHIKV vertical transmission, all of them presented thrombocytopenia, with 76% presenting mild thrombocytopenia (< 150–10
9/L) and 12%, severe thrombocytopenia (< 50–10
9/L) [
4]. In another study conducted with 19 children diagnosed with neonatal CHIKV, 89.4% presented thrombocytopenia, and this result was associated with severe neonatal disease and led to the administration of multiple supportive interventions [
5]. In addition to the afore mentioned symptoms, a study of eight infants showed that half of them exhibited hyperalgesia and respiratory distress, and two cases resulted in death [
9]. Another study showed that early transmission of CHIKV (before 16 weeks of gestation) resulted in fetal death without malformations, with viral genome detected in the amniotic fluid, placenta and fetal brain [
19]. When maternal infection occurs at the end of gestation, it is estimated that 12% of newborns are symptomatic, and most develop severe manifestations, such as meningoencephalitis [
19‐
21]. A study during the intrapartum period indicated a vertical transmission rate of approximately 50% for viremic women, suggesting that this period is critical for transmission to the newborn [
5].
In vertical transmission, the virus is inoculated directly into the fetal bloodstream, bypassing the usual dermal pathway to the lymphatic system and spreading directly into the circulatory system to infect organs, where viral replication continues [
5,
7]. In addition, high maternal viral load, virus tropism to specific target organs, and neonatal host factors may contribute to disease severity [
20].
An important point is that the delivery route does not contribute to infection, and infection is not avoided when delivery is by cesarean section, as evidenced in another study [
18]. Although chikungunya virus is a significant maternal and child threat [
9,
20], adequate research is lacking in South America [
22‐
25].
For pregnant women in endemic areas, health professionals should maintain active surveillance for febrile conditions accompanied by arthralgia. There is also a risk of asymptomatic infection during pregnancy, which demands even greater attention at the time of evaluation [
10]. Investigating suspected arbovirus deaths and understanding the role of infection in unfavorable outcomes is a challenge, especially in a location with more than 30 years of dengue virus, Zika virus and chikungunya virus transmission [
26,
27].
While the infection of pregnant women with Zika virus appears to have a more severe effect on neonates during the first months of gestation, with chikungunya virus, infection is more severe when it occurs at the end of gestation. After these two deaths and the recent introduction of CHIKV in Brazil, along with the presence of several other arboviruses, further research is needed to understand chikungunya deaths and the factors associated with severe clinical cases and atypical manifestations.